Anti-HER-2×anti-CD3 Bi-specific Antibodies Inhibit Growth of HCT-116 Colorectal Carcinoma Cells in Vitro and in Vivo |
Ren, Hui
(Department of General Surgery, the Second Hospital, Jilin University)
Li, Jun (Department of Hematology and Oncology, China-Japan Union Hospital of Jilin University) Liu, Jing-Jing (Department of General Surgery, the Second Hospital, Jilin University) Guo, Hui-Ling (Department of General Surgery, the Second Hospital, Jilin University) Jiang, Tao (Department of General Surgery, China-Japan Union Hospital of Jilin University) |
1 | Albarello L, Pecciarini L, Doglioni C (2011). HER2 testing in gastric cancer. Adv Anat Pathol, 18, 53-9. DOI |
2 | Argyriou AA, Kalofonos HP (2009). Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Mol Med, 15, 183-91. DOI |
3 | Bang YJ, Van Cutsem E, Feyereislova A, et al (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, 376, 687-97. DOI |
4 | Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1999). Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res, 58, 2825-31. |
5 | Chatenoud L (1993). CD3 antibody treatment stimulates the functional capability of regulatory T cells. Novartis Found Symp, 252:279-86; discussion 286-90. |
6 | Cuello M, Ettenberg SA, Clark AS, et al (2001). Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligandmediated apoptosis in breast and ovarian cancer cell lines that over-express erbB- 2. Cancer Res, 61, 4892-900. |
7 | Huang L, Chen S, Zha X, et al (2012). Expression feature of CD3, , and Zap-70 in patients with chronic lymphocytic leukemia. Hematology, 17, 71-5. DOI |
8 | Jemal A, Siegel R, Ward E, et al (2009). Cancer statistics, 2009. CA Cancer J Clin, 59, 225-49. DOI ScienceOn |
9 | Kiewe P, Hasmüller S, Kahlert S, et al (2006). Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin Cancer Res, 12, 3085-91. DOI |
10 | Liu HQ, Zhang SL, Song S (2012). HER-2/neu and TOPIIa expression in gastric cancer reflect disease severity. Hepatogastroenterology, 59, 1290-3. |
11 | Morishita A, Gong J, Nomura T, et al (2010). The use of protein array to identify targetable receptor tyrosine kinases for treatment of human colon cancer. Int J Oncol, 37, 829-35. |
12 | Nishio J, Feuerer M, Wong J, Mathis D, Benoist C (2010). Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor-specified peripheral niche constraints. J Exp Med, 207, 1879-89. DOI |
13 | Schroeder P, Lindemann C, Dettmar K, et al (2011). Trifunctional antibodies induce efficient antitumour activity with immune cells from head and neck squamous cell carcinoma patients after radio-chemotherapy treatment. Clin Transl Oncol, 13, 889-98. DOI |
14 | Somlo G, Martel CL, Lau SK, et al (2012). A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer. Breast Cancer Res Treat, 131, 899-906. Epub 2011 Nov 1. DOI |
15 | Xia L, Yuan YZ, Xu CD, et al (2002). Effects of epidermal growth factor on the growth of human colorectal cancer cell and the implanted tumor of nude mice. World J Gastroenterol, 8, 455-8. |